Month: February 2022

PRAX-114 Phase 2/3 monotherapy MDD Aria Study topline results expected in June 2022 PRAX-944 Phase 2a ET topline results expected in May 2022; to include open-label and placebo-controlled withdrawal data PRAX-222 seamless study in SCN2A-DEE expected to initiate in 2Q22 Cash and investments of $275.9 million as of December 31, 2021 supports runway into 2Q23 BOSTON, Feb. 28, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update, including a video highlighting recent business and pipeline progress, and reported financial results for the fourth quarter and full year 2021. “With...

Full year financial performance ahead of guidance and in-line with sensitivities Funded approximately $820 million in new growth investments Raised $1.3 billion in new corporate level capital through the issuance of Green Bonds; transactions provided for corporate interest savings and maturity extensions Sale of Clearway’s Thermal Business remains on track to close in the first half of 2022 Reaffirming 2022 financial guidance and pro forma CAFD outlook Increased the quarterly dividend by 2% to $0.3468 per share in the first quarter of 2022, or $1.3872 per share annualizedPRINCETON, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) — Clearway Energy, Inc. (NYSE: CWEN, CWEN.A) today reported full year 2021 financial results, including a Net Loss of $(75) million, Adjusted EBITDA of $1,150 million, Cash from Operating Activities of $701...

SAN DIEGO and NAGOYA, Japan, Feb. 28, 2022 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, and Sanwa Kagaku Kenkyusho Co., Ltd. (“Sanwa”), an established, fully integrated pharmaceutical company headquartered in Nagoya, Japan, today announced that the parties have entered into a strategic partnership to exclusively develop and commercialize paltusotine in Japan. Paltusotine is Crinetics’ investigational, orally available nonpeptide somatostatin receptor type 2 (SST2) agonist being evaluated as a treatment for acromegaly and neuroendocrine tumors (NETs), including NETs complicated by carcinoid syndrome. Under the terms of...

TORONTO, Feb. 28, 2022 (GLOBE NEWSWIRE) — Centerra Gold Inc. (“Centerra” or the “Company”) (TSX: CG) (NYSE: CGAU) is pleased to announce the completion of the previously announced acquisition of Gemfield Resources LLC, owner of the Goldfield District Project (“Goldfield”), from Waterton Nevada Splitter, LLC (“Waterton”). Further details on the transaction can be found in Centerra’s February 22, 2022 news release and in the presentation available on Centerra’s website:https://www.centerragold.com/investor/events-presentations About Centerra GoldCenterra Gold Inc. is a Canadian-based gold mining company focused on operating, developing, exploring and acquiring gold properties in North America, Turkey, and other markets worldwide. Centerra operates two mines: the Mount Milligan Mine in British Columbia, Canada, and the Öksüt Mine...

Resubmission to Correct Recently-Identified Technical Issue Conference Call and Webcast at 8:00 am Eastern Time THE WOODLANDS, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the voluntary withdrawal and planned near-term resubmission of the company’s New Drug Application (NDA) for sotagliflozin to correct a technical issue with the submission recently identified by the company. The company promptly notified the U.S. Food and Drug Administration (FDA) about the issue and has been in discussions with the agency to correct the submission. Due to the proximity to the conclusion of the 60-day filing review period, Lexicon determined, after consultation with the FDA, that the withdrawal of the NDA and a subsequent resubmission would be the most appropriate action to provide a complete...

SHANGHAI, China, Feb. 28, 2022 (GLOBE NEWSWIRE) — Q&K International Group Limited (NASDAQ: QK) (“Q&K” or the “Company”), a leading technology-driven long-term apartment rental platform in China, today announced that (i) Mr. Chen Chen, an independent director of the Company, has been appointed as a member of the nominating and corporate governance committee of the board of directors of the Company, effective February 28, 2022, (ii) Mr. Jiamin Chen, current general manager of the investment and financing department of the Company, has been appointed as a director and Vice President of the Company, effective February 28, 2022, and (iii) Mr. Zongquan Yang, current head of product management department and senior manager of IT center of the Company, has been appointed as a director of the Company, effective February 28, 2022. Mr....

SHANGHAI, China, Feb. 28, 2022 (GLOBE NEWSWIRE) — Q&K International Group Limited (NASDAQ: QK) (“Q&K” or the “Company”), a leading technology-driven long-term apartment rental platform in China, today announced that it will change the ratio of the American depositary shares (“ADSs”) representing its Class A ordinary shares from one (1) ADS representing thirty (30) Class A ordinary share to one (1) ADS representing one hundred and fifty (150) Class A ordinary shares. For the ADS holders, the change in the ADS ratio will have the same effect as a one-for-five reverse ADS split. There will be no change to the Company’s Class A ordinary shares. The effect of the ratio change on the ADS trading price on Nasdaq is expected to take place at the open of trading on March 7, 2022 (U.S. Eastern Time). ADS holders of record on the...

Figure 1 Figure 1Figure 2 Figure 2VANCOUVER, British Columbia, Feb. 28, 2022 (GLOBE NEWSWIRE) — NorthWest Copper (“NorthWest” or “the Company”) (TSX-V: NWST) (OTCQX: NWCCF) is pleased to announce that drilling at Kwanika has intersected additional high-grade copper-gold mineralization. Drill holes K-21-220 and K-21-222 returned intervals of very high grades within much longer intervals of significant Cu-Au grades in the vicinity of hole K-21-217 (9.4m of 33.60% copper equivalent “CuEq”) 1. Highlights include:K-21-220: 280 metres2 of 1.08% CuEq3 including 13.85 metres at 4.16% CuEq; K-21-222: 227.60 metres of 0.82% CuEq including 4.0 metres at 5.05% CuEq.The drilling shows the consistency of the high-grade core of Kwanika, with long intervals of material at or near 1% copper equivalent. Within these long intervals are...

Company announcement 5/2022 (28.02.2022) European Energy experienced strong growth and reached new records in 2021. The continuous growth leads European Energy to even more ambitious goals for 2022. European Energy has released its annual report for 2021 with the record numbers of EUR 81.2m in EBITDA and EUR 62.7m in profit before tax. This is an increase of 33 % and 66 % respectively compared to 2020. In 2022 European Energy expects the growth to continue with an EBITDA of EUR 135m and a profit before tax of EUR 100m. During 2021, European Energy started the construction of more than 1 GW of renewable energy capacity in projects divided across 23 different sites – up from 14 the previous year – in the countries of Denmark, Lithuania, Germany, Italy, Poland and Brazil. In 2022, we aim towards a volume of 1.5 GW of new renewable energy...

Paris, February 28, 2022,     Disclosure of Transactions in Own Shares   In accordance with the authorization given by the shareholders’ annual meeting on July 6, 2021 to trade on its own shares and pursuant to applicable law on share repurchase, Kering (LEI: 549300VGEJKB7SVUZR78) declares the following purchases of its own shares (FR0000121485) from February 23 to 25, 2022:  Issuer’s name Issuer’s identifying code Date of transaction Identifying code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares Market (MIC code)KERING 549300VGEJKB7SVUZR78 23/02/2022 FR0000121485 21,000 653.9418 XPARKERING 549300VGEJKB7SVUZR78 24/02/2022 FR0000121485 20,000 615.4634 XPARKERING 549300VGEJKB7SVUZR78 25/02/2022 FR0000121485 16,000 631.2067 XPAR      TOTAL 57,000...